AA

Arumugasamy Anbukkili

Active Director Managing Director DIN 09368749
DIN 09368749 First appointment Oct 2021 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Arumugasamy Anbukkili

Data last updated:

Arumugasamy Anbukkili is a Managing Director at Fine Ark Pharma Private Limited (since 2021). The company operates in Chemicals.

DIN 09368749
Primary Designation Managing Director
Industry Chemicals
First Appointment 21 Oct 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Fine Ark Pharma Private Limited U24239TZ2021PTC037346
Managing Director21 Oct 20212021Active

Board colleagues of Arumugasamy Anbukkili

Directorship timeline

Open interactive timeline →
Fine Ark Pharma Private Limited
Premium access

Shareholding and investment profile for Arumugasamy Anbukkili

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Arumugasamy Anbukkili

Arumugasamy Anbukkili currently holds 1 directorship: Fine Ark Pharma Private Limited (Managing Director, since 21 Oct 2021).

Arumugasamy Anbukkili was first appointed on 21 Oct 2021 as Managing Director at Fine Ark Pharma Private Limited.

The current boards of Arumugasamy Anbukkili's companies include Kanakalingam Koushik Prabhu (Fine Ark Pharma Private Limited), Rajkanth Roshni (Fine Ark Pharma Private Limited), Rupa Ramdas (Fine Ark Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available